BACKGROUND: Pumpless extracorporeal lung assist (PECLA) was developed to support pulmonary function in patients with severe respiratory insufficiency. METHODS: Since 1996, 159 patients with an age ranging from 7 to 78 years were provided with a PECLA system. Fifteen patients were referred to us by air or ground transport after insertion of the system in a peripheral hospital. RESULTS: Main underlying lung diseases were acute respiratory distress syndrome (70.4%) and pneumonia (28.3%). Pumpless extracorporeal lung assist lasted for 0.1 to 33 days, mean 7.0 +/- 6.2 days; cumulative experience was greater than 1,300 days. Successful weaning and survival to hospital discharge was achieved in 33.1% of patients after a mean PECLA support of 8.5 +/- 6.3 days. During PECLA therapy, 48.7% of patients died, mainly as a result of multiorgan failure after a mean interval of 4.8 +/- 5.1 days. Inability to stabilize pulmonary function was noted in 3% of patients only. After PECLA, 30-day mortality was 13.6%. In a subgroup analysis, best outcome was obtained in patients after trauma. CONCLUSIONS: Pumpless extracorporeal lung assist is a simple and efficient method to support patients with deteriorating gas exchange for prolonged periods to allow the lung protective ventilation and transportation. Best indication for use of PECLA is severe hypercapnia and moderate hypoxia.
BACKGROUND: Pumpless extracorporeal lung assist (PECLA) was developed to support pulmonary function in patients with severe respiratory insufficiency. METHODS: Since 1996, 159 patients with an age ranging from 7 to 78 years were provided with a PECLA system. Fifteen patients were referred to us by air or ground transport after insertion of the system in a peripheral hospital. RESULTS: Main underlying lung diseases were acute respiratory distress syndrome (70.4%) and pneumonia (28.3%). Pumpless extracorporeal lung assist lasted for 0.1 to 33 days, mean 7.0 +/- 6.2 days; cumulative experience was greater than 1,300 days. Successful weaning and survival to hospital discharge was achieved in 33.1% of patients after a mean PECLA support of 8.5 +/- 6.3 days. During PECLA therapy, 48.7% of patients died, mainly as a result of multiorgan failure after a mean interval of 4.8 +/- 5.1 days. Inability to stabilize pulmonary function was noted in 3% of patients only. After PECLA, 30-day mortality was 13.6%. In a subgroup analysis, best outcome was obtained in patients after trauma. CONCLUSIONS: Pumpless extracorporeal lung assist is a simple and efficient method to support patients with deteriorating gas exchange for prolonged periods to allow the lung protective ventilation and transportation. Best indication for use of PECLA is severe hypercapnia and moderate hypoxia.
Authors: David J Skoog; Joshua R Pohlmann; David S Demos; Christopher N Scipione; Amit Iyengar; Rebecca E Schewe; Ahmed B Suhaib; Kelly L Koch; Keith E Cook Journal: ASAIO J Date: 2017 Sep/Oct Impact factor: 2.872
Authors: Daniele Camboni; Alvaro Rojas; Peter Sassalos; David Spurlock; Kelly L Koch; Sarah Menchak; Jennifer Singleton; Erika Boothman; Jonathan W Haft; Robert H Bartlett; Keith E Cook Journal: ASAIO J Date: 2013 Nov-Dec Impact factor: 2.872
Authors: Andrea Morelli; Lorenzo Del Sorbo; Antonio Pesenti; V Marco Ranieri; Eddy Fan Journal: Intensive Care Med Date: 2017-01-28 Impact factor: 17.440
Authors: David T Arazawa; Heung-Il Oh; Sang-Ho Ye; Carl A Johnson; Joshua R Woolley; William R Wagner; William J Federspiel Journal: J Memb Sci Date: 2012-02-13 Impact factor: 8.742
Authors: Assad Haneya; Alois Philipp; Maik Foltan; Thomas Mueller; Daniele Camboni; Leopold Rupprecht; Thomas Puehler; Stephan Hirt; Michael Hilker; Reinhard Kobuch; Christof Schmid; Matthias Arlt Journal: Ann Saudi Med Date: 2009 Mar-Apr Impact factor: 1.526